Comments
Dr. Reddy’s Laboratories has launched Reddy-Lenalidomide, a generic equivalent to revlimid (lenalidomide) capsules, in Canada.
Approved by Health Canada, Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada, according to a regulatory filing in BSE.
Dr Reddy’s launches generic version of Librax in US
“Our launch of Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s multiple myeloma and myelodysplastic syndrome (MDS) patient population,” Vinod Ramachandran, Vice-President and General Manager, Dr. Reddy’s Laboratories Canada, said in a statement.
Dr Reddy’s justifies 2DG price of ₹990 per sachet
“Along with this important launch, we have introduced Reddy2Assist Platform, which provides convenient one-stop access to assist prescribers and pharmacists with qualification requirements for patients, as well as patient on-boarding and registration via web portal, telephone or fax.”
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, in blister packs.
Reddy-Lenalidomide is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-risk MSD associated with a cytogenetic abnormality. Approval for this indication is based on red blood cell transfusion independence response rates.
Reddy-Lenalidomide in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.